



The 65th ASH Annual Meeting Abstracts

ONLINE PUBLICATION ONLY

311.DISORDERS OF PLATELET NUMBER OR FUNCTION: CLINICAL AND EPIDEMIOLOGICAL

Recombinant Human Thrombopoietin Combined with Thrombopoietin Receptor Agonists Can Facilitate the Recovery of Platelet after Allogeneic HSCT

Meng Cheng¹, Chong-Sheng Qian¹, Hai-xia Zhou¹, Mingzhu Xu¹, Wen-jie Gong¹, Aining Sun², De-pei Wu^{3,4,5,6}, Sheng-Li Xue⁷

¹ The First Affiliated Hospital of Soochow University, Suzhou, China

² National Clinical Research Center for Hematologic Diseases, The First Affiliated Hospital of Soochow University, Jiangsu Institute of Hematology, Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology, Soochow University, Suzhou, China

³ National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Collaborative Innovation Center of Hematology, Soochow University, Suzhou, China, Suzhou, China

⁴ The First Affiliated Hospital of Soochow University, Suzhou, CHN

⁵ Department of Hematology, The First Affiliated Hospital of Soochow University, Jiangsu Institute of Hematology, National Clinical Research Center for Hematologic Diseases, Suzhou, China

⁶ 2.National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, Collaborative Innovation Center of Hematology, the First Affiliated Hospital of Soochow University, Soochow University, Suzhou, China., Suzhou, China

⁷ Department of Hematology, The First Affiliated Hospital of Soochow University, Jiangsu Institute of Hematology, National Clinical Research Center for Hematologic Diseases, Suzhou, China

Introduction:Thrombocytopenia is a common complication after hematopoietic stem cell transplantation (HSCT) and is strongly associated with transplant-related morbidity and mortality. According to the statistics, the incidence of post-HSCT thrombocytopenia is about 5%-37%. So far, there is no standard treatment regimen for thrombocytopenia after HSCT.

Recombinant human thrombopoietin (rhTPO) can act on megakaryocytes alone and has been widely used in clinical practice. Thrombopoietin receptor agonists (TPO-RAs), another type of drugs that can increase platelet count, has been available since 2008. It can bind to the TPO receptor and cause the conformational change of the receptor, and then activate the JAK2/STATE5 pathway to increase the proliferation of megakaryocyte progenitors and platelet production.

There have been many prospective or retrospective studies discussing the efficacy and safety of rhTPO and TPO-RAs monotherapy in patients with thrombocytopenia. In clinical practice, it is very meaningful to clarify whether the combination of two types of drugs has a synergistic effect when one type of drug has poor efficacy.

M methods This study is a retrospective study in total 12 patients from 2022 to 2023. We selected a total of 6 patients who underwent HSCT in our center during the past year, and used rhTPO combined with avatrombopag to help platelet recovery as observation group. Then, 6 patients treated with rhTPO alone with no statistical difference at baseline were selected as the control group. The basic characteristics of these patients are shown in the table1. All the patients were informed and consented to use rhTPO+TPO-RA (avatrombopag) or rhTPO alone. If platelet count $<20 \times 10^9/L$ during treatment, which will be treated with platelet infusion. All the patients were treated with a modified BUCY regimen as the conditioning regimen and ATG+MMF+cyclosporine+short-range MTX were used to prevent graft vs host disease (GVHD). In observation group, the patients were treated with rhTPO 15000U qd i.m and avatrombopag 40mg qd po, while in control group the patients were treated with rhTPO 15000U qd i.m alone. We recorded the platelet counts of the two groups at day0,7,14,21. Based on this data, the percentage increase and growth rate of platelets were calculated. (the percentage increase: difference in platelet count before and after medication/platelet count before medication $\times 100\%$; the growth rate: difference in platelet count before and after medication/duration of medication.) The above two values were used to evaluate the efficacy of two treatment protocols. Adverse events occurred during treatment including fever, weakness, liver damage, joint pain, bleeding and thrombosis would be recorded to evaluate the safety.

Results In observation group, patients' platelet counts increased by an average was $54 \times 10^9/L$ (range 40 to 69). In control group, the average and median increase in their platelet counts was 22 (range -2 to 49). $P=0.025$ ($P<0.05$). In terms of

the percentage increase in platelet count, the average increase was 452% in observation group VS. 110% in control group. $p=0.022(P<0.05)$. Refer to Figure1a. The average growth rates of platelet counts in observation group were $2.03 \times 10^9/L$ per day. The average rate of increase in control group were $1.07 \times 10^9/L$ per day. $P=0.041(P<0.05)$. The mean platelet count of the two groups at various time points were shown in Figure1b. None of the patients had any adverse events occurred. No patient developed clinical meaningful abnormality of liver function and discontinued avatrombopag or TPO treatment due to intolerance and adverse effects.

Conclusion Our data shows that the treatment protocol of avatrombopag combined with rhTPO may have a greater effect on platelet growth and boost a faster platelet growth rate. Importantly, no additional adverse effects occurred when the addition of avatrombopag.

Disclosures No relevant conflicts of interest to declare.

Table 1: Basic characteristics of two groups of patients

| | observation group(n=6) | control group(n=6) | P value |
|--|------------------------|--------------------|---------|
| Age,yr,median(range) | 39(28-60) | 37(16-55) | 0.668 |
| Sex,male/female,n(%) | 5(83.3)/1(16.7) | 4(66.7)/2(33.3) | 0.549 |
| Disease,n(%) | | | 0.541 |
| Myelodysplastic syndrime | 1(16.7) | 0 (0) | |
| Acute myelogenous leukemia | 3(50) | 5(83.3) | |
| Acute lymphoblastic leukemia | 0(0) | 1(16.7) | |
| Non-hodgkin lymphoma | 2(33.3) | 0 (0) | |
| Time of myeloid hematopoietic reconstruction,median(range) | 12.5(12-20) | 13(11-15) | 0.565 |
| Donor type | | | 0.765 |
| Haploidentical | 4 (66.7) | 4 (66.7) | |
| HLA-identical sibling | 1 (16.7) | 0 (0) | |
| Unrelated | 1 (16.7) | 2 (33.3) | |
| Pre-SCT status,n(%) | | | 0.341 |
| Complete remission | 5(83.3) | 6(100) | |
| Partial remission | 1(16.7) | 0(0) | |
| Active disease | 0(0) | 0(0) | |
| Sten cell source,n(%) | | | 0.734 |
| PBMC | 3(50) | 4 (66.7) | |
| BM+PBMC | 3(50) | 0(0) | |
| CM+PBMC | 0(0) | 2 (33.3) | |
| CD34+ cell dose,cell×10 ⁶ /KG,median(range) | 3.063(1.97-4.41) | 2.80(2.22-3.50) | 0.523 |




Figure1. (a)The percentage of platelet growth per patient. (b) Platelet count at day 0,7,14,21 of medication.

Figure 1

<https://doi.org/10.1182/blood-2023-191091>